NRAS germline variant G138R and multiple rare somatic mutations on APC in colorectal cancer patients in Taiwan by next generation sequencing Figure S1 : Illustration of intra-tumor heterogeneity by two possible mutation pathways. A. Clone successions from one cell with initial mutation in APC gene (red) to final malignant clones with further obtained second and third mutation in KRAS and TP53 (green and blue). The sum of mutation percentage of three serially mutated genes in tumor tissue are 67%, 58% and 33% (tentative cell number). B. Cells with KRAS mutation only may have more proliferation advantage over the cells with APC mutation or cells lacking any mutation. Subsequent mutation may occur in clones with KRAS mutation only. The final genotype will be KRAS dominant instead of APC. 
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